Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 3/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9576425 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8382827 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8381990 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8378626 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL4329889 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL9576378 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL4141304 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL9576392 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL8377436 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL6659196 | 1.00 | LMNA (0.59) | LMNAL3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0268218-B1 | PENETRATION ENHANCERS FOR TRANSDERMAL DELIVERY OF SYSTEMIC AGENTS | WHITBY RESEARCH, Inc. (US) | 1992-05-06 | — | — | EP | claimed |
| US-4886783-A | Penetration enhancers for transdermal delivery of systemic agents | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1989-12-12 | — | — | US | claimed |
| EP-0268218-A2 | Penetration enhancers for transdermal delivery of systemic agents | WHITBY RESEARCH, Inc. (US) | 1988-05-25 | — | — | EP | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12042507-B2 | Compositions and methods of modulating HIF-2A to improve muscle generation and repair | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240190952-A1 | IL-18 Binding Protein (IL-18BP) and Antibodies for Treating Inflammatory Diseases | AB2 BIO SA (CH) | 2024-06-13 | — | — | US | disclosed |
| US-20240181015-A1 | EFFECT OF GHRH ANTAGONISTS IN DIABETES AND OBESITY | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY | 2024-05-23 | — | — | US | disclosed |
| EP-4367086-A2 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS | University of Georgia Research Foundation, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240150311-A1 | COMPOSITIONS AND METHODS FOR INHIBITING IDO1 | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. | 2024-05-09 | — | — | US | disclosed |
| US-11926663-B2 | IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases | AB2 BIO SA (CH) | 2024-03-12 | — | — | US | disclosed |
| US-5043441-A | Enhance penetration of active materials through skin | WHITBY RESEARCH, INC. (US) | 1991-08-27 | — | — | US | disclosed |
| US-5034386-A | Fungicides | WHITBY RESEARCH, INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4886783-A | Penetration enhancers for transdermal delivery of systemic agents | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1989-12-12 | — | — | US | disclosed |
| US-4886545-A | IMPROVE DELIVERY OF PLANT NUTRIENTS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0257086-A4 | Skinpenetration enhancing compositions. | NELSON RES & DEV COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0268218-A2 | Penetration enhancers for transdermal delivery of systemic agents | WHITBY RESEARCH, Inc. (US) | 1988-05-25 | — | — | EP | disclosed |
| EP-0257086-A1 | Skinpenetration enhancing compositions. | NELSON RES & DEV (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4716060-A | ACYCLIC OR HETEROCYCLIC TERTIARY AMIDE | RAJADHYAKSHA VITHAL J (US) | 1987-12-29 | — | — | US | disclosed |
| WO-1987004594-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1987-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | LMNA 3441/4885L3MBTL1 4862/4885MEN1 4840/4885 |
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | SLC29A1, SLC29A2, SLC7A1 | LMNA 1063/4885L3MBTL1 2097/4885MEN1 1409/4885 |
| US-12042507-B2 | Compositions and methods of modulating HIF-2A to improve muscle generation and repair | HIF1A, HIF1AN, MYLK2 | LMNA 621/4885L3MBTL1 3032/4885MEN1 4701/4885 |
| US-20240150311-A1 | COMPOSITIONS AND METHODS FOR INHIBITING IDO1 | IDO1, IDO2, PYGM | LMNA 2265/4885L3MBTL1 3113/4885MEN1 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.